Chrome Holding Co. (MEHCQ)
3.50
-0.10
(-2.78%)
USD |
OTCM |
Dec 05, 13:18
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 96.40M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 5.57% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.5342 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -0.6323 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.85% |
Profile
| Chrome Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcicki in 2006 and is headquartered in San Francisco, CA. |
| URL | http://www.23andme.com |
| Investor Relations URL | https://investors.23andme.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Next Earnings Release | N/A |
| Last Earnings Release | May. 29, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Chrome Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcicki in 2006 and is headquartered in San Francisco, CA. |
| URL | http://www.23andme.com |
| Investor Relations URL | https://investors.23andme.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Next Earnings Release | N/A |
| Last Earnings Release | May. 29, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |